Profile

Cover photo
Advaxis, Inc.
25 followers|11,226 views
AboutPostsPhotosYouTube

Stream

Advaxis, Inc.

Shared publicly  - 
 
Advaxis announced that CEO Dan O'Connor will present at the 2015 Jefferies Global Healthcare Conference on June 1, 2015 at 2 p.m. in New York, NY. Click to read the full press release: http://bit.ly/1SnPDRL
PRINCETON, N.J., May 22, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that Daniel J. O'Connor, President and Chief Executive Officer of Advaxis, will present at the 2015 Jefferies Global Healthcare ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis entered into a non-exclusive research and clinical trial collaboration agreement with Sorrento Therapeutics, Inc. (SRNE) to evaluate combinations of Advaxis's Lm-LLO cancer immunotherapy technology platform, including ADXS-HPV, ADXS-PSA and ADXS-HER2, with Sorrento's fully human antibodies targeting immune checkpoints, including GITR, OX40, LAG-3 and TIM-3. Click to read the full press release: http://bit.ly/1HpRRtU
PRINCETON, N.J. and SAN DIEGO, May 19, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a non-exclusive research and clinical trial collaboration agreement with Sorrento Therapeutics, ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis, Inc. (ADXS) has announced the closing of its latest public offering. http://bit.ly/1IL516s
PRINCETON, N.J., May 5, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) a clinical-stage cancer immunotherapy company, today announced the closing of its previously announced underwritten public offering of 2800000 shares of its common stock at a public offering price of $19.00 per share.
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis Announces Proposed Public Offering of Common Stock http://bit.ly/1IozBCF
PRINCETON, N.J., April 29, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage cancer immunotherapy company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Advaxis expects to grant the underwriters a 30-day ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Data of three studies highlighting the survival outcomes and anti-tumor effects of Advaxis's proprietary Lm-LLO cancer immunotherapy technology was announced at the 2015 American Association for Cancer Research (AACR) Annual Meeting this week. "The data presented at AACR demonstrate that our Lm-LLO technology platform offers significant opportunity to address a number of cancer needs and indications,” stated Daniel O’Connor. http://bit.ly/1HfVmpd
ADXS-HPV Combined with Anti-OX40 or Anti-GITR Antibodies Demonstrates Tumor Growth Inhibition and Prolonged Survival in a Preclinical Study. ADXS-HER2 in Combination with Palliative Radiation Delays Tumor Progression, Prolongs Overall Survival and Maintains Limb Function in Preliminary Data from ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis will host an AACR Research Reception at The Ritz Carlton, Philadelphia on April 21, 2015 at 6:30 p.m. EST. Click now to register: http://bit.ly/1IQOdsX
1
Add a comment...
Have them in circles
25 people
Jeff Anlauf's profile photo
Eduardo Zawadzki's profile photo
Jonah Samuels's profile photo
Michael Higgins's profile photo
Giovanna Beeney's profile photo
Calvin Nokes's profile photo
Bettina Lau's profile photo
Steve D's profile photo
Corsilo Japon's profile photo

Advaxis, Inc.

Shared publicly  - 
 
Advaxis has appointed former Director, Global Regulatory Strategy at Bristol-Myers Squibb, Fred J. Frullo, as our VP, Regulatory Affairs. "Over the past 12 months, Advaxis has significantly expanded and accelerated its clinical development activities requiring an individual of Fred's expertise and experience to manage our regulatory processes," said CMO David Mauro. Find out more: http://bit.ly/1HvMqcH
Former Director, Global Regulatory Strategy for Bristol-Myers Squibb. PRINCETON, N.J., May 21, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed Fred J. Frullo as Vice President, ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis welcomed Thomas W. Hare as the Company's new Vice President, Clinical Operations. As the former Vice President, Drug Development Operations for Incyte Corp., Mr. Hare will oversee clinical operations for Advaxis's multiple Lm-LLO cancer immunotherapy clinical programs. Mr. Hare brings more than 28 years of experience in the biopharmaceutical and contract research organization industries overseeing the management of global commercial and clinical operations, data management, outsourcing and medical writing groups. http://bit.ly/1EgAbfV
Former Vice President, Drug Development Operations for Incyte Corp. and Clinical Manager/Senior Scientist for Bristol-Myers Squibb to Spearhead Advaxis's Clinical Operations as Company Advances Multiple Clinical Programs. PRINCETON, N.J., May 6, 2015 (GLOBE NEWSWIRE) -- Advaxis, ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis Prices $53 Million Public Offering of Common Stock http://bit.ly/1IrcKXj
PRINCETON, N.J., April 30, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage cancer immunotherapy company, today announced the pricing of its previously announced underwritten public offering of 2800000 shares of its common stock at a public offering price of $19.00 per ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis has enhanced the Company's Lm-LLO cancer immunotherapy intellectual property portfolio with two USPTO patents addressing Advaxis's product candidates, ADXS-PSA and ADXS-HER2. Read the full press release here: http://bit.ly/1DT1sVh
ADXS-PSA Patent Covers a Recombinant Listeria Strain Encoded with Recombinant Fusion Peptide of KLK3 Peptide Linked to Non-KLK3 Peptide. ADXS-HER2 Patent Covers Method of Use in Treating HER2/Neu Expressing Tumors, Particularly Osteosarcoma, in Non-Human Animals and Companion Dogs ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Have you registered yet for Advaxis's Research Reception at the AACR Annual meeting? Join us on April 21, 2015 at 6:30 p.m. in Philadelphia: http://bit.ly/1IQOdsX
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis has been included to the Loncar Cancer Immunotherapy Index (LCINDX), the first professional index to track the transformational immunotherapy field within the biotechnology space. Based on current allocations and current share prices, Advaxis is the most heavily weighted stock in LCINDX. Find out more: http://bit.ly/1JvPtC5
PRINCETON, N.J., April 10, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that its stock has been added to the Loncar Cancer Immunotherapy Index (LCINDX). Based on current allocations and current ...
1
Add a comment...
People
Have them in circles
25 people
Jeff Anlauf's profile photo
Eduardo Zawadzki's profile photo
Jonah Samuels's profile photo
Michael Higgins's profile photo
Giovanna Beeney's profile photo
Calvin Nokes's profile photo
Bettina Lau's profile photo
Steve D's profile photo
Corsilo Japon's profile photo
Contact Information
Contact info
Phone
609-452-9813
Address
305 College Rd E‎ Princeton, NJ 08540
Story
Tagline
Advaxis is a biotechnology company developing the next generation of cancer immunotherapies.
Introduction

Advaxis (NASDAQ: ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.